Key result
Alternative renin-angiotensin system targets counteract classical AT1 actions across ~370 registered clinical trials.
This review details the historical discovery, biochemical pathways, and therapeutic potential of the alternative renin-angiotensin system (AT2 receptor, ACE2, angiotensin-(1-7), Mas, alamandine, and MrgD), which counteracts the classical AT1 receptor axis.
Alternative RAS pathways may expand hypertension targets beyond AT1 blockade; leaves open clinical translation from 372 registered trials.
The renin-angiotensin system is the most important peptide hormone system in the regulation of cardiovascular homeostasis. Its classical arm consists of the enzymes, renin, and angiotensin-converting enzyme, generating angiotensin II from angiotensinogen, which activates its AT 1 receptor, thereby increasing blood pressure, retaining salt and water, and inducing cardiovascular hypertrophy and fibrosis. However, angiotensin II can also activate a second receptor, the AT 2 receptor. Moreover, the removal of the C-terminal phenylalanine from angiotensin II by ACE2 (angiotensin-converting enzyme 2) yields angiotensin-(1-7), and this peptide interacts with its receptor Mas. When the aminoterminal Asp of angiotensin-(1-7) is decarboxylated, alamandine is generated, which activates the Mas-related G-protein-coupled receptor D, MrgD (Mas-related G-protein-coupled receptor type D). Since Mas, MrgD, and the AT 2 receptor have opposing effects to the classical AT 1 receptor, they and the enzymes and peptides activating them are called the alternative or protective arm of the renin-angiotensin system. This review will cover the historical aspects and the current standing of this recent addition to the biology of the renin-angiotensin system.
No takes yet. Share an insight, caveat, or question.
Bäder et al. (2024) conducted a review in Cardiovascular homeostasis and renin-angiotensin system-related diseases. Alternative renin-angiotensin system (ACE2, angiotensin-(1-7), Mas, alamandine, MrgD, AT2 receptor) vs. Classical renin-angiotensin system (ACE, angiotensin II, AT1 receptor) was evaluated. The alternative renin-angiotensin system (AT2R, ACE2, Ang-(1-7), Mas, alamandine, and MrgD) counteracts classical AT1 receptor actions and offers novel therapeutic targets across 372 registered trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: